Hema Pharmaceuticals is engaged in the production and supplying of Bedaquiline Fumarate. It is an effective diarylquinoline antimycobacterial drug used in the combination with other antituberculosis medications for the treatment of multidrug resistant tuberculosis. It is a fumarate salt prepared from equimolar amounts of bedaquiline and fumaric acid. It is used in combination therapy for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme that is essential for the replication of the mycobacteria. It has a role as an anti-tubercular agent and an ATP syntheses inhibitor.
Features of Bedaquiline Fumarate:
- Used to treat active tuberculosis
- Highly effective
- Great composition
- Longer shelf life